Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Services
Services
Date issued
2015Journal title
Arthritis and Rheumatology
Type of content
Publicación de congreso
